Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Belite Bio Inc BLTE

Healthcare Biotechnology
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty... see more

Recent & Breaking News (NDAQ:BLTE)

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

GlobeNewswire March 17, 2025

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire March 17, 2025

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire March 11, 2025

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

GlobeNewswire March 4, 2025

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

GlobeNewswire February 27, 2025

Belite Bio Announces Registered Direct Offering of $15 Million

GlobeNewswire February 5, 2025

Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007

GlobeNewswire November 27, 2024

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire November 12, 2024

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

GlobeNewswire November 5, 2024

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

GlobeNewswire November 3, 2024

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

GlobeNewswire October 14, 2024

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

GlobeNewswire October 8, 2024

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

GlobeNewswire September 10, 2024

Belite Bio to Participate in Three Upcoming Investor Conferences

GlobeNewswire September 3, 2024

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

GlobeNewswire September 1, 2024

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire August 9, 2024

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire August 8, 2024

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

GlobeNewswire August 5, 2024

Belite Bio to Present at the JonesHealthcare Seaside Summit

GlobeNewswire July 8, 2024

Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan

GlobeNewswire June 12, 2024